---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-024789"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:53:42.180385+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunocore Q1 KIMMTRAK sales $70.3M (+36% YoY); brenetafusp ASCO data; cash $832.8M

## Summary
- KIMMTRAK net sales $70.3M, up 36% YoY; US $50.0M, Europe $19.0M, international $1.4M.
- Net loss $24.4M ($0.49/sh) vs $19.4M ($0.40/sh) in Q1 2023; R&D $57.5M, SG&A $39.3M.
- Cash $832.8M as of Mar 31, 2024, including $390.2M net from Feb 2024 convertible notes; plans to repay $50M loan.
- Brenetafusp Phase 1/2 data in late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (May 31).
- KIMMTRAK launched in 7 additional countries since Jan 2024; now in 17 countries.

## SEC filing metadata
- accession: 0001140361-24-024789
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036124024789/0001140361-24-024789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036124024789/ef20028669_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-024789
- JSON: https://secwatch.observer/filing/0001140361-24-024789.json
- Plain text: https://secwatch.observer/filing/0001140361-24-024789.txt

## Key facts
- Earnings Releases
  Immunocore Holdings plc reported the first quarter ended March 31, 2024 results: revenue Total net product revenue ... was $70.3 million in the first quarter of 2024, net income Net loss for the first quarter of 2024 was $24.4 million, EPS The first quarter basic and diluted loss per share was $0.49.
  - Period: the first quarter ended March 31, 2024
  - Revenue: Total net product revenue ... was $70.3 million in the first quarter of 2024
  - Net income: Net loss for the first quarter of 2024 was $24.4 million
  - EPS: The first quarter basic and diluted loss per share was $0.49
  - Result: reported results
  source text: On May 8, 2024, Immunocore Holdings plc (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024, as well as other recent corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671927/000114036124024789/0001140361-24-024789-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.